You are here
The Leukemia and Lymphoma Resource Center or LLRC aims to provide access to the latest research findings in leukemia and lymphoma in the form of publications, podcasts and interviews to international healthcare professionals.
The LLRC will particularly serve professionals with an interest in the treatment of Leukemia and/or Lymphoma residing in Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden or Switzerland. In the future, the LLRC will also develop online learning modules and case studies focusing on treatment.
The LLRC is supported by the Elsevier journal Leukemia Research.
This satellite forum was held on Thursday 12 June 2014, before the 19th EHA congress in Milan.
During the forum, unmet needs in the treatment of lymphoma patients were addressed, with a strong focus on the latest developments in CD30-targeted therapy.There was also an update on recent clinical trials that could change the landscape of treatment of CD30+ haematological malignancies during the coming years. A series of challenging patient cases were presented and used as a springboard to initiate a forum-wide exchange of information and experience on the daily management of CD30+ lymphomas.
This site will be regularly updated with webcast clips from the satellite forum.
These webcast modules aim to provide education for physicians on the approved brentuximab vedotin data within the licensed indications, and are available to view as separate education modules. The expert faculty, Dr. Anna Sureda and Dr. Martin Hutchings will cover: an introduction to brentuximab vedotin, mode of action, the Phase I and II clinical data for HL and sALCL and the recently released long term survival analysis. Modules also include transplant ineligible patients and safety updates.